Cost-Consequence Analysis of Sacubitril/Valsartan versus Enalapril in Chronic Heart Failure Patients with Reduced Ejection Fraction

Purpose: The rising prevalence of heart failure (HF) in midlife years in Indians is posing an economic challenge. Sacubitril/valsartan demonstrated a significant risk reduction of cardiovascular deaths by 20% and HF rehospitalizations by 21% versus enalapril but has a higher drug cost. High cost is...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Sameer Bhaskar GOKHALE, Saumitra RAY, Vijay Kumar CHOPRA, Uday JADHAV, Gauri BILLA
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca 2021-07-01
Cyfres:	Applied Medical Informatics
Pynciau:	enalapril costs and cost analysis (cca) heart failure medical economics sacubitril/valsartan
Mynediad Ar-lein:	https://ami.info.umfcluj.ro/index.php/AMI/article/view/811
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!